StockData
Treace Medical Concepts, Inc. logo

Treace Medical Concepts, Inc. (TMCI) stock

TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/3031% below fair value
$4.31−0.04 (-0.92%)

Close on Nov 20, 2026Market cap $280.30MP/E –Yield –

Treace Medical Concepts free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Treace Medical Concepts's free cash flow for the twelve months ending Jun 30, 2026 was -$25.05M. For fiscal 2025 it was -$29.49M. The highest annual figure on record is -$5.56M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.49M–
FY2024Dec 31, 2024-$48.76M–
FY2023Dec 31, 2023-$46.03M–
FY2022Dec 31, 2022-$45.49M–
FY2021Dec 31, 2021-$19.90M–
FY2020Dec 31, 2020-$5.56M–
FY2019Dec 31, 2019-$8.88M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.90M–
Q1 FY2026Mar 31, 2026$4.18M+537.9%
Q4 FY2025Dec 31, 2025-$10.42M–
Q3 FY2025Sep 30, 2025-$11.90M–
Q2 FY2025Jun 30, 2025-$7.82M–
Q1 FY2025Mar 31, 2025$655.00K–
Q4 FY2024Dec 31, 2024-$7.28M–
Q3 FY2024Sep 30, 2024-$14.71M–
Q2 FY2024Jun 30, 2024-$15.63M–
Q1 FY2024Mar 31, 2024-$11.15M–
Q4 FY2023Dec 31, 2023-$1.72M–
Q3 FY2023Sep 30, 2023-$13.01M–
Q2 FY2023Jun 30, 2023-$12.57M–
Q1 FY2023Mar 31, 2023-$18.74M–
Q4 FY2022Dec 31, 2022-$7.69M–
Q3 FY2022Sep 30, 2022-$13.34M–
Q2 FY2022Jun 30, 2022-$15.73M–
Q1 FY2022Mar 31, 2022-$8.72M–
Q4 FY2021Dec 31, 2021-$4.65M-297.1%
Q3 FY2021Sep 30, 2021-$10.20M–
Q2 FY2021Jun 30, 2021-$4.40M–
Q1 FY2021Mar 31, 2021-$642.00K–
Q4 FY2020Dec 31, 2020$2.36M–
Q3 FY2020Sep 30, 2020-$4.26M–
Q2 FY2020Jun 30, 2020-$2.09M–
Q1 FY2020Mar 31, 2020-$1.57M–

More Treace Medical Concepts figures

See a number that looks wrong?